Literature DB >> 32206606

Primary hyperparathyroidism and hypertension.

Sarah B Fisher1, Nancy D Perrier1.   

Abstract

Although untreated primary hyperparathyroidism is associated with increased cardiovascular mortality, controversy exists regarding the therapeutic effects of parathyroidectomy on cardiovascular health. This review will examine the evidence linking primary hyperparathyroidism (PHPT) and cardiovascular disease, specifically hypertension, and evaluate the available literature regarding the natural history of hypertension after successful parathyroidectomy. 2020 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Primary hyperparathyroidism (PHPT); cardiovascular mortality; hypertension; parathyroid; parathyroidectomy

Year:  2020        PMID: 32206606      PMCID: PMC7082275          DOI: 10.21037/gs.2019.10.21

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  67 in total

1.  Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors?

Authors:  Jeffrey L Anderson; Ryan C Vanwoerkom; Benjamin D Horne; Tami L Bair; Heidi T May; Donald L Lappé; Joseph B Muhlestein
Journal:  Am Heart J       Date:  2011-08       Impact factor: 4.749

2.  The important players in primary hyperparathyroidism.

Authors:  Jens Bollerslev
Journal:  Clin Endocrinol (Oxf)       Date:  2013-08-09       Impact factor: 3.478

3.  Impairment of endothelium-independent vasodilation in patients with hypercalcemia.

Authors:  T Neunteufl; R Katzenschlager; C Abela; K Kostner; B Niederle; F Weidinger; T Stefenelli
Journal:  Cardiovasc Res       Date:  1998-11       Impact factor: 10.787

Review 4.  Circulating parathyroid hormone and risk of hypertension: A meta-analysis.

Authors:  Yi Zhang; Dian-Zhong Zhang
Journal:  Clin Chim Acta       Date:  2018-03-26       Impact factor: 3.786

5.  Noradrenergic blood pressure dysregulation and cytosolic calcium in primary hyperparathyroidism.

Authors:  H Schiffl; T Sitter; S M Lang
Journal:  Kidney Blood Press Res       Date:  1997       Impact factor: 2.687

Review 6.  Coincident diabetes mellitus and primary hyperparathyroidism.

Authors:  W H Taylor; A A Khaleeli
Journal:  Diabetes Metab Res Rev       Date:  2001 May-Jun       Impact factor: 4.876

7.  Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey.

Authors:  O M Gutiérrez; W R Farwell; D Kermah; E N Taylor
Journal:  Osteoporos Int       Date:  2010-09-17       Impact factor: 4.507

8.  Vitamin D, PTH and the risk of overall and disease-specific mortality: Results of the Longitudinal Aging Study Amsterdam.

Authors:  Jamila El Hilali; Elisa J de Koning; Adriana J van Ballegooijen; Paul Lips; Evelien Sohl; Harm W J van Marwijk; Marjolein Visser; Natasja M van Schoor
Journal:  J Steroid Biochem Mol Biol       Date:  2015-12-08       Impact factor: 4.292

9.  Patients with normocalcemic primary hyperparathyroidism may have similar metabolic profile as hypercalcemic patients.

Authors:  Feyza Yener Ozturk; Selvinaz Erol; Muhammed Masum Canat; Savas Karatas; Idris Kuzu; Sezin Dogan Cakir; Yuksel Altuntas
Journal:  Endocr J       Date:  2015-11-17       Impact factor: 2.349

10.  Increased mortality and morbidity in mild primary hyperparathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS).

Authors:  Ning Yu; Peter T Donnan; Robert W V Flynn; Michael J Murphy; David Smith; Andrew Rudman; Graham P Leese
Journal:  Clin Endocrinol (Oxf)       Date:  2009-12-18       Impact factor: 3.478

View more
  1 in total

1.  The effect of parathyroidectomy compared to non-surgical surveillance on kidney function in primary hyperparathyroidism: a nationwide historic cohort study.

Authors:  Josephine Matzen; Lise Sofie Bislev; Tanja Sikjær; Lars Rolighed; Mette Friberg Hitz; Pia Eiken; Anne Pernille Hermann; Jens-Erik Beck Jensen; Bo Abrahamsen; Lars Rejnmark
Journal:  BMC Endocr Disord       Date:  2022-01-06       Impact factor: 2.763

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.